Intradermal Bleomycin Injections Into Normal Human Skin
- 1 May 1994
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 130 (5) , 577-583
- https://doi.org/10.1001/archderm.1994.01690050045006
Abstract
Background: Intralesionally injected bleomycin is a useful agent for the treatment of recalcitrant warts. The mechanism of action in wart therapy has been thought to be due to DNA and antiviral effects. To further characterize the inflammatory response to intralesional bleomycin injections, we examined the clinical, histologic, and immunopathologic response to intradermal bleomycin injections in normal human skin. Results: Four volunteers were each given four intradermal bleomycin injections (0.01 to 0.5 U/mL) into normal human skin to establish a dose response. These injections induced a localized time and dose-dependent inflammatory reaction and persistent postinflammatory hyperpigmentation. Nine biopsy specimens from two volunteers were taken at different time points after intradermal bleomycin injections (0.1 to 1.0 U/mL) into normal human skin. Routine histologic study demonstrated dyskeratosis and necrosis of epidermal keratinocytes and eccrine epithelium associated with a prominent neutrophilic infiltrate, closely resembling histopathologic findings seen in neutrophilic eccrine hidradenitis. Expression of HLA-DR and intercellular adhesion molecule 1 was induced on keratinocytes; intercellular adhesion molecule 1 was upregulated, and endothelial leukocyte adhesion molecule 1 was induced on superficial dermal blood vessels. Conclusions: These findings suggest that intradermal bleomycin injection is either directly or indirectly cytotoxic to keratinocytes and eccrine epithelium. Expression and upregulation of activation antigens and cell adhesion molecules suggest that a cellular immune system response and proinflammatory cytokine secretion occur after intralesional bleomycin injection into normal human skin. Histopathologic findings at some injection sites resemble neutrophilic eccrine hidradenitis. (Arch Dermatol. 1994;130:577-583)Keywords
This publication has 11 references indexed in Scilit:
- Tumor necrosis factorJournal of the American Academy of Dermatology, 1991
- Intralesional bleomycin sulfate therapy for warts. A novel bifurcated needle puncture techniqueArchives of Dermatology, 1991
- Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis.The Journal of Experimental Medicine, 1989
- Neutrophilic eccrine hidradenitis: Evidence implicating bleomycin as a causative agentCancer, 1988
- Therapeutic evaluation for intralesional injection of bleomycin sulfate in 143 resistant wartsPublished by Elsevier ,1988
- Neutrophilic eccrine hidradenitis associated with induction chemotherapyJournal of Cutaneous Pathology, 1987
- Reduced dose of bleomycin in the treatment of recalcitrant wartsJournal of the American Academy of Dermatology, 1986
- Bleomycin in the treatment of recalcitrant wartsJournal of the American Academy of Dermatology, 1983
- Neutrophilic eccrine hidradenitis. A distinctive type of neutrophilic dermatosis associated with myelogenous leukemia and chemotherapyArchives of Dermatology, 1982
- Characterization of chain breakage in DNA induced by bleomycinBiochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesis, 1974